Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C

Table 1 Characteristics of patients studied

	All	SVRs	Relapsers	NVRs	P value
Number of patients	87	41	26	20
Gender (female/male)	47/40	17/24	20/6	10/10	N.S.
Age (yr)	59 (50-66)	52 (44-63)2	63 (54-66)2	62 (51-67)	0.01252
Fibrosis stage (F0-2/F3,4)1	38/24	23/43	12/84	3/1234	< 0.00013 0.01544
Inflammatory grade (A0,1/A2,3)1	25/37	14/133	8/12	3/123	0.03843
Genotype (1/2)2	57/28	17/24234	21/424	19/034	0.00042 < 0.00013 0.02814
Platelet count (× 104/μL)	14.2 (11.7-18.8)	15.7 (12.7-19.5)3	14.4 (11.4-17.9)	11.1 (9.1-15.7)3	0.01163
Prothrombin time (%)	97 (91-110)	99 (91-111)	96 (91-110)	97 (88-103)	NS
Albumin (g/dL)	4.2 (4.0-4.5)	4.3 (4.2-4.6)3	4.2 (3.9-4.5)	4.2 (3.9-4.2)3	0.01413
Total bilirubin (mg/dL)	0.8 (0.6-1.0)	0.7 (0.5-1.1)	0.7 (0.6-1.0)	0.9 (0.7-1.0)	NS
AST (IU/L)	45 (32-69)	40 (27-59)3	43 (32-59)	57 (46-88)3	0.01873
ALT (IU/L)	51 (35-86)	51 (30-75)	47 (33-94)	58 (42-95)	NS
γ-GTP (IU/L)	37 (23-67)	47 (23-83)	28 (21-43)4	44 (27-110)4	0.02054
ALP (U/L)	261 (212-345)	244 (208-267)3	287 (220-389)	358 (223-422)3	0.00343
Hyaluronic acid (ng/mL)	80 (42-169)	47 (33-94)3	86 (54-168)4	163 (97-301)34	0.00033 0.02764
HCV RNA (logIU/mL)	6.3 (5.2-6.8)	5.7 (4.8-6.8)3	6.4 (5.8-6.7)	6.7 (6.3-7.1)3	0.01093
APRI	0.91 (0.54-1.68)	0.82 (0.40-1.16)3	0.95 (0.57-1.58)	1.59 (0.85-2.84)3	0.00833
FIB-4	2.57 (1.66-4.00)	2.04 (1.49-2.70)23	2.95 (2.14-4.49)2	4.52 (2.82-5.96)3	0.01082 0.00013
Vs (m/s)
Pretreatment	1.36 (1.16-1.72)	1.27 (1.11-1.49)3	1.39 (1.15-1.57)4	1.80 (1.54-2.01)34	0.00073 0.00364
End of treatment	1.27 (1.12-1.56)	1.19 (1.07-1.37)3	1.23 (1.12-1.55)4	1.64 (1.43-2.06)34	< 0.00013 0.01244
1 yr after treatment	1.20 (1.06-1.50)	1.10 (1.00-1.22)23	1.20 (1.12-1.80)2	1.66 (1.30-1.95)3	0.01922 0.00133
2 yr after treatment	1.17 (1.03-1.48)	1.05 (0.95-1.16)23	1.41 (1.08-2.01)2	1.61 (1.36-2.37)3	0.00962 0.00043

¹Fibrosis stage, inflammatory grade and genotype performed by a chi square testing;

²Comparison between SVRs and Relapsers;

³Comparison between SVRs and NVRs;

⁴Comparison between Relapsers and NVRs. Data are shown as median (interquartile range). AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GTP: γ-glutamyltranspeptidase; ALP: Alkaline Phosphatase; APRI: Aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4; NVR: Non-virological responders; SVR: Sustained virological responder.

Table 2 Changes of deduced fibrosis stages by interferon plus ribavirin therapy

	SVRs	Relapsers	NVRs
	(n = 13)	(n = 12)	(n = 16)
2-point reduction	9 (69.2)	2 (16.7)	0
1-point reduction	2 (15.4)	1 (8.3)	5 (31.3)
No changes	2 (15.4)	6 (50.0)	9 (56.2)
1-point progression	0	3 (25.0)	2 (12.5)
Interval (yr)	2.0 (1.0-2.5)	2.8 (1.7-3.1)	1.6 (0.7-2.4)

SVR: Sustained virological response; NVR: Nonvirological response.

Table 3 Characteristics of genotype1 patients studied

	All	SVRs	Relapsers and NVRs	P value
Number of patients	57	17	40
Gender (female/male)	34/23	7/10	25/15	NS
Age (yr)	59 (50-66)	51 (41-58)	62 (54-67)	0.0016
Fibrosis stage (F0-F2 /F3,4)1	25/17	12/0	13/17	< 0.0001
Inflammatory grade (A0,1/A2,3)1	16/26	6/6	10/20	NS
Platelet count (× 104/μL)	14.0 (10.7-18.3)	15.4 (13.0-19.5)	13.2 (9.4-17.4)	NS
Prothrombin time (%)	99 (91-111)	102 (91-110)	98 (92-112)	NS
Albumin (g/dL)	4.2 (4.0-4.5)	4.4 (4.2-4.6)	4.2 (4.0-4.4)	0.0496
Total bilirubin (mg/dL)	0.8 (0.6-1.0)	0.8 (0.5-1.1)	0.8 (0.6-1.0)	NS
AST (IU/L)	47 (32-71)	38 (28-63)	48 (35-77)	NS
ALT (IU/L)	50 (35-90)	50 (30-92)	52 (36-91)	NS
γ-GTP (IU/L)	33 (22-51)	37 (15-66)	30 (23-50)	NS
ALP (U/L)	267 (212-379)	246 (187-262)	314 (215-416)	0.0053
Hyaluronic acid (ng/mL)	95 (46-173)	51 (21-98)	114 (68-180)	0.0076
HCV RNA (logIU/mL)	6.4 (5.8-7.0)	6.0 (5.2-7.1)	6.4 (6.1-6.9)	NS
APRI	0.91 (0.56-1.69)	0.80 (0.45-1.09)	1.05 (0.63-1.73)	NS
FIB-4	2.69 (1.64-4.46)	1.66 (1.26-2.53)	3.34 (2.23-4.63)	0.0014
Vs (m/s); Before treatment	1.44 (1.17-1.75)	1.28 (1.04-1.40)	1.56 (1.20-1.83)	0.0142

¹Fibrosis stage and Inflammatory grade performed by a χ² testing. Comparison between SVRs and non-SVRs (Relapser/NVRs). Data are shown as median (interquartile range). AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GTP: γ-glutamyltranspeptidase; ALP: Alkaline Phosphatase; APRI: Aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4; NVR: Non-virological responders; SVR: Sustained virological responder.

Table 4 Logistic regression analysis for predictive factors in interferon plus ribavirin therapy for genotype1 patients

	β	Standard error	P value	95%CI
Age (yr)	-0.347	0.006	0.008	-0.0271-(-0.0043)
ALP (U/L)	-0.196	0.001	NS	-0.0021-(-0.0003)
Vs (m/s)	-0.196	0.162	NS	-0.5773-(-0.0721)

Vs: Velocity of shear wave; ALP: Alkaline phosphatase.